Unknown

Dataset Information

0

Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights.


ABSTRACT: The Androgen Receptor (AR) is emerging as an important factor in the pathogenesis of breast cancer (BC), which is the most common malignancy among females worldwide. The concordance of more than 70% of AR expression in primary and metastatic breast tumors implies that AR may be a new marker and a potential therapeutic target among AR-positive breast cancer patients. Biological insight into AR-positive breast cancer reveals that AR may cross-talk with several vital signaling pathways, including key molecules and receptors. AR exhibits different behavior depending on the breast cancer subtype. Preliminary clinical research using AR-targeted drugs, which have already been FDA-approved for prostate cancer (PC), has given promising results for AR-positive breast cancer patients. However, since the prognostic and predictive value of AR positivity remains uncertain, it is difficult to identify and stratify patients that would benefit from AR-targeted therapies. Herein, through a review of preclinical studies, clinical studies, and clinical trials, we summarize the biology of AR, its prognostic and predictive value, as well as its therapeutic implications by breast cancer molecular subtype.

SUBMITTER: Anestis A 

PROVIDER: S-EPMC7024330 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): NCT00004205

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7192742 | BioStudies
2017-01-01 | S-EPMC5366816 | BioStudies
2016-01-01 | S-EPMC5221599 | BioStudies
2019-01-01 | S-EPMC6387478 | BioStudies
2014-01-01 | S-EPMC4122770 | BioStudies
2020-01-01 | S-EPMC7492540 | BioStudies
2019-01-01 | S-EPMC6852746 | BioStudies
2020-01-01 | S-EPMC7230528 | BioStudies
2020-01-01 | S-EPMC7543239 | BioStudies
2009-01-01 | S-EPMC2667820 | BioStudies